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The development of genomic tests is one of the most significant technological advances in medical testing in
recent decades. As these tests become increasingly available, so does the need for a pragmatic framework to
evaluate the evidence base and evidence gaps in order to facilitate informed decision-making. In this article we
describe such a framework that can provide a common language and benchmarks for different stakeholders of
genomic testing. Each stakeholder can use this framework to specify their respective thresholds for decision-
making, depending on their perspective and particular needs. This framework is applicable across a broad range of
test applications and can be helpful in the application and communication of a regulatory science for genomic
testing. Our framework builds upon existing work and incorporates principles familiar to researchers involved in
medical testing (both diagnostic and prognostic) generally, as well as those involved in genomic testing. This
framework is organized around six phases in the development of genomic tests beginning with marker
identification and ending with population impact, and highlights the important knowledge gaps that need to be
filled in establishing the clinical relevance of a test. Our framework focuses on the clinical appropriateness of the
four main dimensions of test research questions (population/setting, intervention/index test, comparators/reference
test, and outcomes) rather than prescribing a hierarchy of study designs that should be used to address each
phase.
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Evidence-based decision makingIntroduction
The development of genetic and genomic tests is one of
the most significant technological advances in medical
testing in recent decades. A growing interest in “perso-
nalized” or “precision” medicine, commercial interests
seeking return on investment, and limited regulatory
oversight in many countries has resulted in increased
availability of genomic tests. This environment has created
a number of issues to determining the most appropriate
point in time to adopt a new test in clinical practice which
cannot be determined solely by availability, marketing, or
regulatory approval.
Medical testing, in general, lags behind therapeutics in
the understanding and application of rigorous evidence-* Correspondence: Jennifer.S.Lin@kpchr.org
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reproduction in any medium, provided the orbased evaluation, and has particularly lacked a focus on
patient outcomes. Because medical testing primarily pro-
vides information that may change patient management
which indirectly affects patient outcomes, the direct im-
pact on patient health can be difficult to assess. How-
ever, not only are diagnostic issues a greater source of
medical errors and safety concerns than therapeutics,
diagnostic testing also directs the majority of health care
expenditure [1]. A focus on the net benefit of testing to
patients (and a population of patients) is common to all
stakeholders in medicine, and thus should be the unify-
ing goal for any test evaluation framework.
Despite the importance of medical testing in patient
management, the profit margins for the development of
new tests are often low, compared to new pharmaceuti-
cals, so there may be little incentive for diagnostic test
developers to support clinical testing beyond that
required for regulatory approval [2]. Generating and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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complicated by a set of terms and concepts unfamiliar to
the majority of clinicians and their patients (Additional
file 1). Genomic tests also have multiple applications in
health care in addition to diagnosis, including screening,
risk assessment, prognosis, and treatment selection
(Table 1). Individual tests may have different roles within
the same disease (e.g., Oncotype Dx [Genomic Health,
Redwood City, CA] is used in both prognosis and treatment
prediction of breast cancer), as well as across different
diseases (e.g., KRAS testing is used to guide treatment
decisions in both colorectal cancer and lung cancer).
There have been a number of models or frameworks
designed to specifically structure the evaluation of gen-
omic test development (Additional files 2 and 3) [3-16].
The majority of these frameworks build on the well-
recognized ACCE (Analytic validity, Clinical validity,
Clinical Utility, and Ethical, legal and social issues)
framework [4-7,17,18], while others utilize the four or
five phases of translational medicine (T1-T5) research
[8-11]. The ACCE framework, as well as other models,
are derived from a larger body of frameworks and
criteria for the evaluation of medical tests in general
(e.g. imaging, biomarkers) [18,19]. The majority of
these frameworks are phased or tiered models that
make a distinction between categories of evidence that
address technical efficacy (analytic validity), diagnostic
accuracy (clinical validity), and patient outcome efficacy
(clinical utility) [19]. However, none of these diagnostic
or prognostic models have been universally adopted by
regulatory science agencies, health systems, or professional
groups as the standard for the evaluating the evidence
needed to inform decision-making around test regulatory
approval, clinical use, reimbursement or guidelines
implementation.
While these frameworks provide valuable insight into
approaching the evaluation of genomic testing, each has
important limitations. First, frameworks are too nar-
rowly focused on a single testing role (e.g., screening), a
particular clinical context (e.g., newborn screening), orTable 1 Multiple clinical roles of genetic tests in clinical pract
Type Purpose Definition
Diagnostic Screening Detection or exclusion of a characteristic
or disease in asymptomatic persons
Diagnosis Rule in or rule out conditions in
symptomatic persons
Prediction Risk assessment Risk of future disease or morbidity from
disease in people without the disease




Determine, predict, or monitor response
and/or adverse effects of treatmentone particular aspect or phase of evaluation (e.g., test
validation). We believe that a single, inclusive framework
would provide a common language across different
stakeholders (e.g., clinicians, laboratorians, researchers,
policy makers, test developers, and patients) despite
their varying perspectives and needs. Second, frame-
works such as the translational research models that
specify phases of research from bench to bedside do not
describe in sufficient detail the evidence needed within
each phase of its development. From experience, we
have found that general models lack specificity, are
therefore difficult to operationalize and subsequently
inconsistently applied. Third, some categories of frame-
works are extremely comprehensive (involving detailed
checklists or series of questions), and thus are better
suited for identifying all possible research that might
inform use of a genomic test without consideration of
which research is necessary (and sufficient) before adop-
tion in any specific clinical scenario. Together, these
issues point to the critical need for a consistent and
comprehensible framework for the efficient development
and dissemination of genomic tests in order to facilitate
informed decision-making.
Our aim is to describe a framework for assessing the evi-
dence base for genomic tests (from discovery to clinical
adoption) that builds upon existing published frameworks
for evaluating genomic tests, without necessarily specify-
ing any particular threshold of evidence for regulatory
approval or clinical implementation. We anticipate this
framework will be helpful in communicating where
evidence for a particular diagnostic or prognostic test is
missing, and inform the types of research needed before
test implementation.
Evaluation framework to define the evidence base for
genomic tests
The proposed framework specifies six phases in the devel-
opment of genomic tests and focuses on the important
knowledge gaps that must be addressed before the tests can
achieve clinical relevance (Figure 1 and Figure 2). Likeice
Examples
Fecal DNA to screen for colorectal cancer, SRY genotype
to determine fetal sex in first-trimester
Lynch syndrome testing in patients with colorectal cancer, CFTR
testing in patients with suspected cystic fibrosis, Factor V Leiden
or prothrombin gene testing in patients with thromboembolic disease
Cardiogenomic profile in order to assess risk of future cardiovascular
disease, BRCA testing in women at high risk for breast cancer
Oncotype DX panel to assess prognosis in women with early
stage breast cancer, BRCA testing in women with breast cancer
CYP2C19 gene to predict response to clopidigrel in patients with
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Figure 1 Evaluation framework for genomic test development. Tests should be evaluated within a given clinical context (i.e. specify disease
or health condition, type of patient, proposed test role, desired outcomes, and current practice or clinical alternatives).
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development research [20], with the exception that it adds
a Phase 0 for discovery and divides Phase 4 (post-marketing
surveillance in drug development) into separate phases
reflecting comparative effectiveness research and popula-
tion impact. The framework incorporates the concepts and
terminology used in previous frameworks distinguishing
between technical efficacy (analytic validity), diagnostic
accuracy (clinical validity), and patient outcome efficacy
(clinical utility).
The phases of development are laid out from the
"ground up" to illustrate the cumulative aspect of know-
ledge development that relies on solid foundations of
pre-clinical evidence and proceeds through successively
more applicable clinical studies (Figure 1). Although dis-
played linearly in this model, not all research in this
arena proceeds in an orderly fashion. Test development
research is highly iterative with possible modifications of
the assay or test occurring at any phase of development.
Intersecting with each phase of development (rows) are
columns that specify the three main clinical roles of tests,
namely ‘Diagnostic’ (including screening and diagnosis),
‘Predictive’ (including risk assessment and prognosis) and
‘Treatment’ (including selection and monitoring) (Figure 2).
These intersections allow the user to visualize which
aspects of development are shared across all test roles and
which are unique to a particular role.Phase 0: Biomarker identification and assay development
This phase encompasses the vast majority of genomic
research, including agnostic genome-wide association
studies (GWAS) and candidate gene approaches. An online
catalog of GWAS published findings, for example, includes
over 1000 publications and over 5000 disease-single
nucleotide polymorphism (SNP) associations to date [21].
Maximum efficiency and success in assay development
should begin with research targeting areas of clinical need,
thereby ensuring that tests offer the greatest clinical value.
This phase also includes the early development of
promising molecular biomarkers into genomic assays.
There are multiple technical test aspects affecting assay
development, including the selection of variant(s) to be
evaluated, selection of a technology or platform for
genotyping, and determination of sample and sample
handling conditions. This phase should establish the
initial analytic validity of the chosen assay that includes
the basic technical performance of the assay (i.e., analytic
accuracy, precision, and reproducibility). Ideally, this phase
would result in a (well-defined) assay suitable for possible
application in a specific disease or health condition that
could be assessed in subsequent steps.
Phase 1: Initial test performance and assay refinement
A test’s initial clinical test performance is almost always
examined in highly selected populations that are not
Figure 2 Framework for phased evaluation of new genetic tests in relation to proposed roles.
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be used on. For example, tests may be conducted in per-
sons with known disease compared to healthy controls,
or in persons at very high risk for having the outcome(s)
of interest (higher pre-test probability than the intended
patients). For diagnostic tests, test performance is gener-
ally compared to a reference standard assay using mea-
sures such as sensitivity, specificity and predictive values.
The approaches used to measure initial test perform-
ance, however, rely on the current state and accuracy of
the science. For example, the diagnostic accuracy of a
new genomic assay to measure cystic fibrosis transmem-
brane conductance regulator (CFTR) genotype would be
compared with a functional assay, such as the sweat test,
which is still the current standard for diagnosing cystic
fibrosis [22]. The sweat test is not a perfect reference
standard, but is better than mutation-based alternatives
that lack demonstration of functional defects. However,
lack of a true reference standard may result in mislead-
ing results if the newer test is actually superior [23]. For
prognostic tests, initial assay performance is measured
through strength of association between the assay result
(e.g., presence of molecular variant[s]) and the develop-
ment of the outcome (e.g., progression to a moreadvanced stage of disease, or development of disease
complications). For tests that are used to select or monitor
a treatment, measures of test performance may include
association between the test result and an intermediate
outcome, such as drug metabolism (e.g., serum level of
endoxifen, the active form of tamoxifen after metabolism
through CYP2D6), or pathophysiological response (e.g.,
tumor shrinkage, platelet aggregation). Using intermediate
outcomes can also be misleading if these outcomes do not
sufficiently discriminate between different treatment
responses or are not robustly associated with true health
effects in the patient [24]. If intermediate outcomes are
used for efficiency at initial proof-of-concept phases, they
should be sufficiently linked to patient outcomes through
existing research.
Phase 1 also includes ongoing refinement of the assay’s
technical performance. It is often necessary to refine the
assay based on initial test performance by characterizing
sample handling conditions or pre-analytic variables that
result in superior performance of the test. For example,
there may be changes in requirements for micro-dissection
to isolate tumor tissue from contamination by normal tis-
sue for a test of somatic mutations, or changes in the buffer
conditions to stabilize a sample during transfer to a
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validation and assay refinement can sometimes lead to sig-
nificant changes in the assay. As such, it is important for
test development research to be explicit about the similar-
ities and differences in iterative “versions” of assays. Fecal
Deoxyribonucleic acid (DNA) testing, for example, has
undergone multiple iterations during its development as a
potential screening tool for colorectal cancer. As a result,
the currently available assay compared to previously test
versions (different biomarkers and different technologies)
[25], which has resulted in discrepancies amongst different
clinical recommendations [26,27].
Phase 2: Test validation and generalizability
Although, studies in this phase often use the same out-
come measures as studies in Phase 1 (i.e., measures of
diagnostic accuracy), they establish the performance of
the test in populations in which the test is intended to
be used. The differences in study design and population
between Phase 1 and Phase 2 often lead to differences in
test performance [28]. In the development of a genomic
assay to screen for colon cancer, for example, the initial
test performance in Phase 1 would establish the assay's
ability to differentiate known cases from controls. In
Phase 2 however, the performance of the assay is evalu-
ated in a sample of all patients eligible for colorectal
cancer screening, which allows determining the assay's
performance in the intended population and its feasibility
under less idealized conditions. Phase 1 research (initial
test validation) showed that early versions of fecal DNA
testing had very high sensitivity (around 90%) but Phase 2
research conducted in a screening population showed
much lower sensitivities (around 25 to 50%), and also
revealed problems with test implementation in a clinical
setting. These Phase 1-Phase 2 discrepancies led to sub-
stantial alterations in subsequent versions of the fecal
DNA assays [29].
Phase 3: Clinical test performance and health impacts
While previous phases focus solely on the diagnostic or
prognostic ability of these tests, research in Phase 3
addresses the clinical impact and net benefit (i.e., trade-
off between benefits and harms) to patients from using
the test compared to not using the test. Outcomes for
phase 3 can include the impact of testing on patient
management and treatment decisions (e.g., increased
cancer surveillance, monitoring for progression or recur-
rence, or choice in treatment regimen) and subsequent
patient health outcomes (e.g., morbidity, mortality,
adverse effects and quality of life). Established diagnostic
accuracy or risk prediction (clinical validity) does not
necessarily translate into improved health outcomes
(clinical utility). This lack of effect on health outcomes
may occur because a test may provide informationwhich does not (or cannot) lead to changes in treatment
or management options. Even if management options
exist, they may not be effective in improving health
outcomes. Alternatively a genomic test may identify a
genotype with incomplete or variable penetrance, or the
harms (or other tradeoffs) of testing outweigh or
mitigate the clinical benefits.
One well known example of genomic testing with estab-
lished clinical utility is BRCA1/2 testing (e.g., BRACAna-
lysis, Myriad Genetics Inc., Salt Lake City, UT). There has
been significant research in evaluating patient outcomes
from bilateral prophylactic mastectomy to prevent breast
cancer in carriers of BRCA 1/2 mutations, demonstrating
improved survival and quality of life [30]. In contrast, gen-
omics tests for Factor V Leiden (FVL) or prothrombin
mutations in patients with idiopathic venous thrombo-
embolism (VTE) (or in their family members) displays
good clinical validity, but lacks evidence of clinical utility.
Although an increased risk for VTE recurrence (in
patients) or VTE occurrence (in family members) is
well-established, knowledge of mutation status is un-
likely to significantly benefit patients or their family
members [31]. Thus, this phase’s key goal is to demon-
strate that the test result triggers a clinical action that
leads to improved health outcomes.
Phase 4: Comparison with existing tests
Research in this phase aims to answer the question of
whether the test result provides added clinical value
above and beyond other clinical information already
available, or compared to existing tests. Whilst genomic
tests can be novel tests for conditions for which no tests
currently exist, it is always important to consider the
existing standard of care: whether the new test performs
better than any existing tests, or whether the new test
has equal diagnostic/prognostic ability, but is less inva-
sive or less expensive. For example, clinicians need to
know whether an assay for cytochrome P450 (CYP)
2C19 variants is superior to existing platelet functioning
testing in predicting response to clopidogrel in persons
with acute coronary syndrome (or undergoing percutan-
eous coronary intervention). This issue of “comparative
effectiveness” is paramount for genomic tests designed
for risk prediction or prognosis. Ten new biomarkers
have recently been identified that are strongly associated
with breast cancer risk in older women at the genome-
wide significance level [32]. However, the performance
of a risk prediction model using these biomarkers, as
measured by the area under the curve (AUC), is only
slightly better than risk models that use four traditional
non-genetic risk factors. Thus, the new biomarkers do
not provide sufficient additional information beyond
traditional risk factors to warrant adoption, despite a
highly statistically significantly association. Genetic
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have similarly demonstrated a failure to provide a signifi-
cant improvement over models using only traditional
risk factors and do not offer other advantages in terms
of cost, accessibility, or acceptability.
Phase 5: Population impacts
The final phase of this framework evaluates the new
test’s population impacts, including its implications for
the family, community, or society as a whole (including
ethical and/or legal issues). For example, an accurate
method has been developed to determine fetal gender by
detection of the sex-determining region Y (SRY) geno-
types in maternal blood during the first trimester, which
should only be present if the fetus is male [35]. Even if
this test has moved far along the phases of development,
for many societies the use of this test for non-medical
purposes would have major ethical and moral issues.
The cost of new tests also has major implications for
multiple stakeholders, so this phase might include health
economic evaluations. For example, while it is theoretic-
ally possible to screen all newly diagnosed colorectal
cancer patients for mutations in Lynch Syndrome genes,
the cost of germline testing would far outweigh the costs
saved from identifying individuals with mutations and
implementing programs for early detection or preven-
tion of cancer [36-38]. Instead, other approaches to
identify high-risk individuals for testing have been
recommended based on the clinical characteristics of the
patient or the results of preliminary laboratory screening
tests [27,39,40].
Strengths of the proposed framework
This framework provides a common language and
benchmarks that can be used by diverse stakeholders.
This is important because while test developers may
have expertise in particular genetic tests, these tests are
likely to be evaluated increasingly by those with less-
specialized knowledge as a test advances through phases
of development. As such, we have incorporated general
principles familiar to those doing research in medical
testing generally (diagnostic and prognostic) as well as
those doing research in genomic testing (e.g., ACCE and
laboratory-based validation principles). We have also
tried to use shared terminology and concepts that cor-
relate with both medical testing and pharmaceutical
development.
This framework does not prescribe a hierarchy of
study designs that should be used to answer the ques-
tions in each phase because the risk of bias within any
given study (considering both design and implementa-
tion) is more important than the type of study per se.
Multiple study designs may be possible within each of
our proposed phases. Instead, our framework focuses onthe transitions in the four main dimensions of test
research questions (population/setting, intervention/
index test, comparators/reference test, outcomes) as the
main organizing principle to categorize the hierarchy of
evidence for test development/performance across the
“phases” of research (Figure 2). Phases 0 and 1 focus on
the establishing the index test (I). The pivotal transition
from Phase 1 to Phase 2, involves evaluating the clinical
performance of the assay in populations (P) for whom it
is designed. Phase 3 represents a further substantial
change in outcomes (O) of interest from the clinical
accuracy of testing (Phases 1 & 2) to the net impact of
the test on patient health outcomes (clinical utility). In
Phase 4 the pivotal transition is the comparison (C) to
existing tests or clinical data used to inform clinical
decision making about what test works better (or has
less harm), or the added value of a test to managing
patient care. Phase 5 represents another pivotal change
in outcomes (O), with a shift in focus to population level
outcomes, often including cost, and societal level impli-
cations of testing beyond the individual patient.
Finally, our proposed framework incorporates different
clinical roles of genetic tests across the multiple phases
of evaluation. As such, it avoids the “silo” approach of
having multiple different frameworks for each different
role of tests and highlights shared research aims across
different test roles. For example, demonstrating an asso-
ciation between genetic variant and clinical outcome of
interest is common to all potential future uses of genetic
tests in Phase 0. In contrast, in Phase 1 the key out-
comes for a genetic test depend on its intended use as a
screening/diagnostic test versus prognostic or pharma-
cogenomic test. In Phase 3, studies of different clinical
applications may differ in both study population and
outcomes. For example, a study of BRCA1/2 testing for
risk assessment (prediction) in asymptomatic women
might evaluate how well the test classifies a woman’s risk
of developing breast cancer over a specific time period,
which could modify screening recommendations or
prophylactic management strategies. A study of the same
test’s use in determining appropriate treatment options
in women who already have breast cancer, on the other
hand, would focus on the test's ability to distinguish
between those who did and didn’t respond to specific
treatments [41]. Highlighting these shared and separate
research aims may allow test developers and researchers
to focus on potential clinical uses of new genetic tests.
Implications of proposed framework to relevant
stakeholders
We have synthesized across many existing models
[4-7,17-19] to describe a unifying framework that
allows stakeholders to comprehend the state of the
evidence (and evidence gaps) for any given genomic
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because their development and dissemination is
both rapid and iterative, rather than an orderly one-way
path from discovery to adoption in clinical practice.
While a phased evaluation scheme allows for efficient,
ethical research planning, in reality, it is not a rigid
progression in medical testing or drug development. An
orderly progression may characterize the early pre-
clinical stages (Phases 0 and 1 in our framework), but
it is less common beyond these stages [19]. While it
may not be necessary (or realistic) for test developers
to conduct research that moves through the phases one
level at a time, this framework allows decision makers
to understand the existing evidence in the context of
the entire evidence landscape hierarchy.
As genomic testing is increasingly disseminated into
clinical practice, clinicians and their patients will
encounter these tests on a regular basis. As a result, we
anticipate the framework will be useful in communicating
to clinicians and their patients, what evidence is available
for a genomic tests and/or what evidence would be needed
before considering using it for routine clinical use.
Through using the framework it should be quite apparent
that, for example, the latest media report of a new gene-
disease association is only at the start of the evidence-
gathering (Phase 0), and thus deserves little of the pre-
cious clinical time available for determining current pa-
tient care options.
Our framework also allows different stakeholders to
specify different thresholds for decision-making, depending
on their perspective and particular needs (e.g., for explor-
ation, further development or discontinuation, regulation,
clinical uptake, insurance coverage, dissemination, practice
guideline development, or marketing). Regardless of where
different stakeholder may choose to set their threshold, the
framework usefully organizes evidence into two main
stages: pre-clinical (Phases 0 and 1) where a test may be in
various phases of development but not ready for clinical
adoption and clinical phases (Phases 2 through 5), whereby
increasing certainty of clinical impact is investigated. It is
important to articulate these initial pre-clinical Phases 0
and 1 in a genomic testing framework, because often
discovery research (e.g., agnostic GWAS) or early/initial
validity testing (e.g., case control studies in patient with
known disease and healthy controls) pushes the early
adoption of genomic testing into clinical practice. Although
Phase 2 research may establish clinical validity in the
relevant patient populations it does not translate directly
into improved patient outcomes and therefore may be an
adequate threshold for some stakeholders (e.g., test regula-
tors), but not others (e.g., payers, health care delivery
systems).
Medical laboratory testing regulation is much more
limited than, for example, the regulation of new drugs.In both the United States (US) and Europe, regulation is
based heavily on technical performance and demonstration
of some clinical relevance, but not on patient outcomes
[42-44]. In the US, the vast majority of genomic tests in
the US are laboratory-developed tests (LDT), not actively
regulated by the U.S. Food and Drug Administration
(FDA), but instead regulated by the Centers for Medicare
and Medicaid Services for the overall quality of laboratory
testing under the Clinical Laboratory Improvement
Amendments (CLIA), which addresses implementation
of testing largely after the clinical adoption [45]. The
Secretary's Advisory Committee on Genetic Testing
(SACGT) has recommended that the FDA be respon-
sible for the review, approval, and labeling of all new
genetic tests that have moved beyond the basic research
phase (i.e., Phase 0), focusing on the evaluation of analytical
validity and clinical validity (i.e., Phases 1 and 2) as well as
on claims made by the test developer about its clinical
utility (i.e., Phases 3 through 5) [46].
Our proposed framework could help unify perspectives
and shared understanding in the same way that the four
phases of drug development allow a clearly understood
benchmarking process for approval and usage of new
pharmaceuticals. If this framework were incorporated
into the FDA's developing “evidence-based regulatory
science” approach, regulatory agencies could be explicit
on what an appropriate level of evidence (taking into
consideration different populations, comparator tests,
and outcomes) might be for a given assay and what con-
stitutes a similar enough (vs. new/different) assay. Other
stakeholders (e.g., payers or health systems) could simi-
larly reflect upon and be explicit about their threshold of
evidence before uptake, as different bodies will inevitably
have different perspectives.
Our suggested framework is intended to facilitate
ongoing discussion and developmental activities among
manufacturers, test researchers, systematic reviewers,
regulators, and other policy-makers, as well as to facili-
tate understanding among clinicians and patients. We
believe our framework is broad enough to be applied to
a wide variety of genomic testing, however, we realize
that the complexities and rapid advances within genomics
(next generation sequencing) and related fields (proteomics,
metabolomics) will necessitate re-evaluating and tailoring
our framework over time. If our effort reflects a useful
synthesis of existing frameworking efforts to date, it may
allow more consistency in definitions for terms and
concepts going forward and provide a platform for future
collaborative efforts.
Conclusions and future directions
The field of genomics is one of the potentially most
important developments in health care in the 21st century,
holding out the promise of revolutionizing medicine
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lieve that in order to achieve their potential, and to avoid
inappropriate use, genomic tests need to be much more
broadly understood, and dialogue between different types
of users needs to be facilitated. Our proposed framework
improves upon the efforts of others, and offers unique fea-
tures, including specifying in more detail the clinical ques-
tions and changes in research focus that accompany the
clinical development of a genomic test. If this framework
is applied generally, it will help users understand the state
of the science for a given genomic application and to ar-
ticulate their own clinical thresholds for evidence that may
be required for a test to be adopted. This, in turn, could re-
duce confusion, minimize the possibility for inappropriate
use, and enhance innovation.
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